Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Baxter
Farmers Insurance
Daiichi Sankyo
Dow
Merck
Medtronic
Mallinckrodt
AstraZeneca
Teva

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,259,388

« Back to Dashboard

Which drugs does patent 9,259,388 protect, and when does it expire?

Patent 9,259,388 protects GELNIQUE and is included in one NDA.

This patent has seventeen patent family members in twelve countries.
Summary for Patent: 9,259,388
Title:Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Abstract: The invention relates to a method for treating overactive bladders and a device for storing and administering non-occluded oxybutynin topical compositions.
Inventor(s): Gochnour; Scott (Salt Lake City, UT), Subramanyan; Venkatesh (Salt Lake City, UT), Kimball; Michael W. (Salt Lake City, UT)
Assignee: Watson Pharmaceuticals, Inc. (Salt Lake City, UT)
Application Number:14/059,671
Patent Claim Types:
see list of patent claims
Use; Composition; Device; Formulation;

Drugs Protected by US Patent 9,259,388

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan Sales Llc GELNIQUE oxybutynin chloride GEL;TRANSDERMAL 022204-001 Jan 27, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,259,388

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,920,392 Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,259,388

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2011144397 ➤ Subscribe
Mexico 2011011642 ➤ Subscribe
Mexico 338166 ➤ Subscribe
South Korea 20120030078 ➤ Subscribe
Japan 5795817 ➤ Subscribe
Japan 2014144957 ➤ Subscribe
Japan 5485377 ➤ Subscribe
Japan 2012526124 ➤ Subscribe
European Patent Office 2427172 ➤ Subscribe
Germany 10772664 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Teva
Covington
Boehringer Ingelheim
Johnson and Johnson
Chubb
Medtronic
Deloitte
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot